olmesartan medoxomil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic) 1985 144689-63-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • olmesartan medoxomil
  • olmetec
  • CS-866
  • CS866
Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle.
  • Molecular weight: 558.60
  • Formula: C29H30N6O6
  • CLOGP: 3.54
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 2
  • TPSA: 154.34
  • ALOGS: -4.88
  • ROTB: 11
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.02 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 26 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
April 25, 2002 FDA DAIICHI SANKYO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sprue-like enteropathy 661.67 11.25 137 34437 606 63453842
Malabsorption 385.47 11.25 126 34448 3946 63450502
Intestinal villi atrophy 153.85 11.25 34 34540 216 63454232
Colitis microscopic 116.07 11.25 69 34505 9270 63445178
Hyperkalaemia 93.89 11.25 131 34443 54072 63400376
Dehydration 83.39 11.25 245 34329 173109 63281339
Acute kidney injury 81.46 11.25 321 34253 263094 63191354
Hyponatraemia 76.10 11.25 180 34394 111720 63342728
Renal failure 75.45 11.25 185 34389 117467 63336981
Systemic lupus erythematosus 74.93 11.25 12 34562 208906 63245542
Device related thrombosis 73.87 11.25 30 34544 1755 63452693
Blood pressure increased 70.38 11.25 221 34353 161841 63292607
Wound 69.62 11.25 5 34569 163258 63291190
Diarrhoea 64.72 11.25 633 33941 714733 62739715
Off label use 56.60 11.25 184 34390 674278 62780170
Coeliac disease 55.52 11.25 50 34524 12747 63441701
Infusion related reaction 54.68 11.25 33 34541 245488 63208960
Drug intolerance 54.11 11.25 53 34521 308608 63145840
Hypertensive crisis 51.62 11.25 52 34522 15234 63439214
Renal impairment 51.47 11.25 134 34440 88221 63366227
Glossodynia 50.83 11.25 17 34557 178859 63275589
Maternal exposure during pregnancy 49.81 11.25 29 34545 220033 63234415
Lower respiratory tract infection 48.79 11.25 7 34567 132300 63322148
Blood pressure inadequately controlled 47.26 11.25 31 34543 4947 63449501
Blood immunoglobulin M increased 46.58 11.25 19 34555 1124 63453324
Chronic gastritis 46.12 11.25 25 34549 2816 63451632
Therapeutic product effect decreased 45.83 11.25 24 34550 193163 63261285
Oligohydramnios 44.84 11.25 33 34541 6333 63448115
Drug ineffective 44.82 11.25 360 34214 1044405 62410043
Hepatic enzyme abnormal 44.72 11.25 33 34541 6359 63448089
Bradycardia 44.65 11.25 113 34461 73114 63381334
Blood immunoglobulin A decreased 43.98 11.25 19 34555 1298 63453150
Hypotension 43.85 11.25 276 34298 272328 63182120
Microvillous inclusion disease 43.35 11.25 8 34566 16 63454432
Synovitis 43.20 11.25 24 34550 186894 63267554
Treatment failure 42.59 11.25 28 34546 199015 63255433
Gallbladder polyp 42.35 11.25 16 34558 771 63453677
Blood immunoglobulin G increased 41.20 11.25 22 34552 2405 63452043
Completed suicide 41.11 11.25 14 34560 145659 63308789
Hypertensive emergency 40.45 11.25 20 34554 1862 63452586
Cerebral infarction 40.24 11.25 57 34517 23836 63430612
Swelling 36.99 11.25 58 34516 275320 63179128
Hypokalaemia 35.71 11.25 131 34443 103673 63350775
Weight decreased 35.44 11.25 265 34309 276533 63177915
Discomfort 35.19 11.25 24 34550 167350 63287098
Blood urea increased 34.58 11.25 56 34518 26323 63428125
Collagen disorder 34.32 11.25 10 34564 211 63454237
Blood pressure decreased 34.22 11.25 95 34479 64927 63389521
Blood creatinine increased 33.77 11.25 115 34459 87729 63366719
Metabolic acidosis 32.25 11.25 74 34500 44995 63409453
Pain 32.20 11.25 254 34320 740374 62714074
Gastritis 32.12 11.25 66 34508 37237 63417211
Product use issue 31.99 11.25 44 34530 220476 63233972
Asthenia 31.87 11.25 334 34240 383270 63071178
Alopecia 31.87 11.25 87 34487 337449 63116999
Helicobacter infection 31.77 11.25 6 34568 92779 63361669
Syncope 31.44 11.25 137 34437 117248 63337200
Toxicity to various agents 31.40 11.25 54 34520 247196 63207252
Rheumatic disorder 31.30 11.25 20 34554 3052 63451396
Renal disorder 30.37 11.25 60 34514 32914 63421534
Pancreatic toxicity 29.07 11.25 6 34568 26 63454422
Blood glucose increased 29.05 11.25 106 34468 83650 63370798
Dizziness 28.39 11.25 358 34216 429567 63024881
Arthropathy 28.27 11.25 53 34521 234739 63219709
Contraindicated product administered 28.13 11.25 47 34527 217601 63236847
Heart rate irregular 27.24 11.25 46 34528 22375 63432073
Cardiac failure congestive 27.17 11.25 111 34463 92322 63362126
Hypocalvaria 26.90 11.25 6 34568 40 63454408
Lymphocytic infiltration 26.74 11.25 12 34562 898 63453550
Abdominal discomfort 26.49 11.25 88 34486 320797 63133651
Gravitational oedema 26.39 11.25 13 34561 1201 63453247
Enteritis 25.82 11.25 27 34547 8259 63446189
Intentional product use issue 24.73 11.25 20 34554 127872 63326576
Nail disorder 23.33 11.25 32 34542 12983 63441465
Multiple fractures 23.21 11.25 26 34548 8592 63445856
Joint swelling 23.03 11.25 96 34478 327570 63126878
Musculoskeletal stiffness 22.81 11.25 41 34533 184577 63269871
Exposure during pregnancy 22.59 11.25 31 34543 155516 63298932
Autoimmune enteropathy 22.40 11.25 4 34570 6 63454442
Diverticulum 22.28 11.25 30 34544 11961 63442487
Putamen haemorrhage 22.08 11.25 7 34567 198 63454250
General physical health deterioration 22.07 11.25 48 34526 201354 63253094
Enterocolitis 21.67 11.25 24 34550 7834 63446614
Gastrooesophageal reflux disease 21.45 11.25 106 34468 95533 63358915
Impaired healing 21.15 11.25 15 34559 102527 63351921
Product use in unapproved indication 21.04 11.25 41 34533 179039 63275409
Hypersensitivity 21.03 11.25 85 34489 292600 63161848
Spleen congestion 20.94 11.25 6 34568 119 63454329
Hepatic enzyme increased 20.73 11.25 50 34524 202278 63252170
Blood creatine phosphokinase increased 20.71 11.25 49 34525 30381 63424067
Eye disorder 20.55 11.25 41 34533 22644 63431804
Azotaemia 20.45 11.25 18 34556 4453 63449995
Renal impairment neonatal 20.36 11.25 5 34569 53 63454395
Oesophagitis 19.86 11.25 32 34542 14976 63439472
Skin exfoliation 19.80 11.25 60 34514 43042 63411406
Condition aggravated 19.79 11.25 133 34441 402084 63052364
Coronary artery disease 19.76 11.25 50 34524 32327 63422121
Prerenal failure 19.70 11.25 12 34562 1684 63452764
Eosinophil count 19.55 11.25 3 34571 0 63454448
Chronic kidney disease 18.84 11.25 61 34513 45337 63409111
Death 18.82 11.25 123 34451 374258 63080190
Burn oesophageal 18.25 11.25 6 34568 191 63454257
Glaucoma 18.13 11.25 35 34539 18870 63435578
Large intestine polyp 17.65 11.25 22 34552 8135 63446313
Diverticulitis 17.18 11.25 54 34520 39503 63414945
Anti-transglutaminase antibody increased 17.01 11.25 3 34571 4 63454444
Hypoalbuminaemia 16.77 11.25 26 34548 11779 63442669
Distributive shock 16.62 11.25 10 34564 1373 63453075
Inappropriate antidiuretic hormone secretion 16.54 11.25 30 34544 15432 63439016
Alanine aminotransferase increased 15.98 11.25 104 34470 103666 63350782
Gastritis erosive 15.89 11.25 18 34556 6021 63448427
Hyperuricaemia 15.85 11.25 17 34557 5353 63449095
Electrolyte imbalance 15.52 11.25 34 34540 20042 63434406
Aortic valve calcification 15.50 11.25 7 34567 532 63453916
Confabulation 15.41 11.25 6 34568 314 63454134
Cystitis 15.34 11.25 65 34509 54926 63399522
Decreased appetite 15.24 11.25 206 34368 250846 63203602
Liver injury 15.12 11.25 7 34567 60513 63393935
Breast cancer metastatic 15.06 11.25 25 34549 11993 63442455
Infection 14.96 11.25 69 34505 229104 63225344
Hiatus hernia 14.94 11.25 35 34539 21559 63432889
Cerebrovascular accident 14.69 11.25 105 34469 107919 63346529
Fatigue 14.45 11.25 371 34203 887657 62566791
Renin increased 14.39 11.25 5 34569 189 63454259
Oedema peripheral 14.30 11.25 162 34412 189349 63265099
Abortion spontaneous 14.27 11.25 4 34570 47191 63407257
Blood aldosterone increased 14.17 11.25 5 34569 198 63454250
Blister 14.16 11.25 31 34543 129783 63324665
Product administration error 14.10 11.25 35 34539 22362 63432086
Febrile neutropenia 14.01 11.25 27 34547 118422 63336026
Hypertension neonatal 13.87 11.25 3 34571 17 63454431
Fibromyalgia 13.84 11.25 14 34560 80406 63374042
Hepatorenal failure 13.81 11.25 7 34567 687 63453761
Bradyphrenia 13.80 11.25 18 34556 6962 63447486
Cataract operation 13.76 11.25 16 34558 5506 63448942
Hepatic function abnormal 13.72 11.25 48 34526 37094 63417354
Atrial tachycardia 13.54 11.25 14 34560 4226 63450222
Therapeutic product effect incomplete 13.53 11.25 30 34544 125026 63329422
Ill-defined disorder 13.22 11.25 15 34559 81740 63372708
Aortic dissection 13.18 11.25 10 34564 2008 63452440
Acquired oesophageal web 13.17 11.25 5 34569 244 63454204
Myocardial infarction 12.95 11.25 96 34478 99797 63354651
Hernia 12.95 11.25 24 34550 12550 63441898
Atrial fibrillation 12.88 11.25 108 34466 116528 63337920
Iron deficiency anaemia 12.36 11.25 31 34543 19938 63434510
Mucosa vesicle 12.20 11.25 3 34571 32 63454416
Feeling abnormal 12.18 11.25 129 34445 148263 63306185
Purpura senile 12.15 11.25 6 34568 557 63453891
Gamma-glutamyltransferase 12.11 11.25 3 34571 33 63454415
Hypovolaemia 11.79 11.25 21 34553 10652 63443796
Withdrawal hypertension 11.70 11.25 4 34570 144 63454304
Drug-induced liver injury 11.57 11.25 48 34526 40174 63414274
COVID-19 11.54 11.25 28 34546 113075 63341373
Rhabdomyolysis 11.53 11.25 51 34523 43900 63410548
Renal artery stenosis 11.47 11.25 9 34565 1900 63452548
Chest pain 11.42 11.25 173 34401 215786 63238662
Hepatitis D 11.32 11.25 3 34571 44 63454404
Skin reaction 11.31 11.25 25 34549 14824 63439624

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sprue-like enteropathy 473.73 11.63 101 23278 412 34933140
Malabsorption 341.23 11.63 106 23273 2266 34931286
Gastrointestinal disorder 102.70 11.63 120 23259 33828 34899724
Intestinal villi atrophy 80.24 11.63 19 23360 135 34933417
Colitis microscopic 75.39 11.63 35 23344 2302 34931250
Renal impairment 64.65 11.63 173 23206 94340 34839212
Death 60.42 11.63 109 23270 397940 34535612
Coeliac disease 50.81 11.63 19 23360 721 34932831
Toxicity to various agents 48.31 11.63 38 23341 200324 34733228
Off label use 48.01 11.63 134 23245 419390 34514162
Right atrial hypertrophy 45.72 11.63 18 23361 787 34932765
Syncope 42.35 11.63 146 23233 91305 34842247
Blood pressure increased 41.98 11.63 142 23237 87960 34845592
Hepatic function abnormal 38.51 11.63 89 23290 44274 34889278
Dehydration 38.14 11.63 180 23199 129789 34803763
Hypotension 38.06 11.63 266 23113 221383 34712169
Fractional exhaled nitric oxide increased 37.39 11.63 17 23362 1065 34932487
Diarrhoea 36.79 11.63 410 22969 389502 34544050
Hyperkalaemia 36.78 11.63 116 23263 69273 34864279
Bronchial wall thickening 36.55 11.63 18 23361 1350 34932202
Weight decreased 35.35 11.63 220 23159 176081 34757471
Blood pressure decreased 34.88 11.63 94 23285 51421 34882131
Right ventricular hypertrophy 34.60 11.63 18 23361 1516 34932036
Bronchial secretion retention 34.58 11.63 18 23361 1518 34932034
Drug ineffective 32.79 11.63 176 23203 456575 34476977
Dizziness 30.59 11.63 250 23129 218271 34715281
Aortic valve stenosis 29.89 11.63 20 23359 2683 34930869
Drug abuse 29.05 11.63 15 23364 99081 34834471
Hyperkinetic heart syndrome 28.39 11.63 8 23371 120 34933432
Pulmonary function test abnormal 28.11 11.63 19 23360 2591 34930961
Pulmonary hypoplasia 27.83 11.63 11 23368 486 34933066
Cerebral infarction 27.11 11.63 58 23321 27397 34906155
Interstitial lung disease 26.60 11.63 100 23279 65182 34868370
Gastrooesophageal reflux disease 26.47 11.63 70 23309 37854 34895698
Neutropenia 26.40 11.63 40 23339 156738 34776814
Brain natriuretic peptide increased 25.99 11.63 25 23354 5634 34927918
Gastrointestinal erosion 25.94 11.63 10 23369 413 34933139
Obstructive airways disorder 25.77 11.63 41 23338 15453 34918099
Obstruction 25.09 11.63 18 23361 2701 34930851
Hypertensive crisis 24.89 11.63 30 23349 8721 34924831
Microvillous inclusion disease 24.86 11.63 8 23371 192 34933360
Sensation of foreign body 24.71 11.63 18 23361 2765 34930787
Completed suicide 24.41 11.63 18 23361 98150 34835402
Plantar fasciitis 24.23 11.63 16 23363 2100 34931452
Myoglobin blood increased 23.38 11.63 18 23361 3005 34930547
Chest X-ray abnormal 23.23 11.63 21 23358 4377 34929175
Hyperuricaemia 21.95 11.63 27 23352 8016 34925536
Hypokalaemia 21.94 11.63 87 23292 58127 34875425
Acute kidney injury 21.50 11.63 304 23075 304684 34628868
Lip oedema 21.18 11.63 16 23363 2597 34930955
Gout 20.55 11.63 42 23337 19211 34914341
Anaplastic astrocytoma 19.97 11.63 6 23373 114 34933438
Erosive duodenitis 19.65 11.63 13 23366 1711 34931841
Coronary artery occlusion 19.61 11.63 30 23349 10932 34922620
Atrial fibrillation 19.28 11.63 144 23235 122249 34811303
Tropical sprue 18.93 11.63 3 23376 0 34933552
Papillary renal cell carcinoma 18.84 11.63 7 23372 261 34933291
Loss of consciousness 18.34 11.63 106 23273 82561 34850991
Intestinal intraepithelial lymphocytes increased 17.91 11.63 6 23373 164 34933388
Sleep apnoea syndrome 17.88 11.63 41 23338 20280 34913272
Hypertensive emergency 17.35 11.63 10 23369 1030 34932522
Ischaemic enteritis 17.34 11.63 4 23375 25 34933527
Diastolic dysfunction 17.15 11.63 21 23358 6206 34927346
Treatment failure 17.09 11.63 5 23374 46692 34886860
Haemorrhoids 17.00 11.63 33 23346 14542 34919010
Product use in unapproved indication 17.00 11.63 33 23346 117466 34816086
Hypertension 16.89 11.63 152 23227 136291 34797261
Febrile neutropenia 16.86 11.63 42 23337 136807 34796745
Oligohydramnios 16.68 11.63 7 23372 361 34933191
Infective exacerbation of chronic obstructive airways disease 16.50 11.63 12 23367 1839 34931713
Renal failure 16.45 11.63 146 23233 130411 34803141
Lymphangiectasia intestinal 16.39 11.63 3 23376 4 34933548
Coronary artery disease 15.70 11.63 69 23310 48236 34885316
Chronic gastritis 15.46 11.63 11 23368 1629 34931923
Collagen disorder 15.09 11.63 5 23374 132 34933420
Intervertebral disc degeneration 15.08 11.63 20 23359 6397 34927155
Decreased appetite 14.70 11.63 173 23206 166219 34767333
Histology abnormal 14.48 11.63 6 23373 300 34933252
Jealous delusion 14.34 11.63 6 23373 307 34933245
Atrophy 14.31 11.63 9 23370 1086 34932466
Cardiac failure congestive 14.27 11.63 100 23279 83170 34850382
Disease progression 14.24 11.63 32 23347 108045 34825507
Kidney small 14.13 11.63 4 23375 61 34933491
Intestinal ulcer perforation 13.92 11.63 3 23376 13 34933539
Full blood count abnormal 13.57 11.63 35 23344 18633 34914919
Hypovolaemia 13.42 11.63 23 23356 9211 34924341
Heart sounds abnormal 13.38 11.63 8 23371 882 34932670
Insulin-like growth factor increased 13.27 11.63 9 23370 1234 34932318
Prerenal failure 13.12 11.63 11 23368 2073 34931479
Rectal ulcer haemorrhage 13.12 11.63 4 23375 80 34933472
Transient aphasia 12.86 11.63 6 23373 399 34933153
Blood pressure inadequately controlled 12.77 11.63 12 23367 2628 34930924
Pancytopenia 12.68 11.63 28 23351 95129 34838423
Enterocolitis viral 12.55 11.63 4 23375 93 34933459
General physical health deterioration 12.45 11.63 44 23335 128225 34805327
Thrombocytopenia 12.40 11.63 58 23321 156189 34777363
Erectile dysfunction 12.33 11.63 36 23343 20601 34912951
Hospitalisation 12.22 11.63 12 23367 56890 34876662
Echocardiogram abnormal 12.08 11.63 8 23371 1055 34932497
Renal disorder 12.05 11.63 41 23338 25439 34908113
Palmar-plantar erythrodysaesthesia syndrome 11.71 11.63 31 23348 16764 34916788

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sprue-like enteropathy 1095.69 10.74 233 47091 1085 79695979
Malabsorption 557.03 10.74 179 47145 4853 79692211
Intestinal villi atrophy 225.52 10.74 53 47271 416 79696648
Colitis microscopic 184.28 10.74 101 47223 10667 79686397
Hyperkalaemia 121.27 10.74 232 47092 114166 79582898
Renal impairment 110.96 10.74 271 47053 157512 79539552
Dehydration 105.05 10.74 355 46969 247832 79449232
Diarrhoea 104.72 10.74 884 46440 879605 78817459
Gastrointestinal disorder 90.30 10.74 214 47110 121991 79575073
Off label use 84.92 10.74 267 47057 906948 78790116
Coeliac disease 82.39 10.74 62 47262 11289 79685775
Renal failure 80.23 10.74 282 47042 200686 79496378
Syncope 76.15 10.74 257 47067 179192 79517872
Toxicity to various agents 74.79 10.74 84 47240 421456 79275608
Hypertensive crisis 72.80 10.74 75 47249 20695 79676369
Acute kidney injury 71.02 10.74 539 46785 518865 79178199
Completed suicide 70.15 10.74 29 47295 245738 79451326
Blood pressure increased 69.73 10.74 279 47045 211081 79485983
Hypotension 69.46 10.74 473 46851 439844 79257220
Cerebral infarction 64.36 10.74 105 47219 45571 79651493
Chronic gastritis 63.70 10.74 36 47288 4032 79693032
Weight decreased 62.34 10.74 392 46932 354806 79342258
Microvillous inclusion disease 60.71 10.74 16 47308 209 79696855
Device related thrombosis 59.68 10.74 30 47294 2653 79694411
Drug ineffective 57.57 10.74 391 46933 1080522 78616542
Hypokalaemia 57.34 10.74 202 47122 143838 79553226
Hypertensive emergency 55.74 10.74 29 47295 2756 79694308
Blood pressure inadequately controlled 54.54 10.74 38 47286 6139 79690925
Blood pressure decreased 52.80 10.74 154 47170 99312 79597752
Death 52.65 10.74 167 47157 566347 79130717
Drug intolerance 49.73 10.74 50 47274 264069 79432995
Hepatic function abnormal 48.63 10.74 123 47201 72984 79624080
Collagen disorder 48.29 10.74 14 47310 265 79696799
Hyponatraemia 48.01 10.74 221 47103 177627 79519437
Pericarditis 46.94 10.74 4 47320 104232 79592832
Maternal exposure during pregnancy 44.29 10.74 13 47311 136525 79560539
Blood immunoglobulin G increased 42.92 10.74 25 47299 2964 79694100
Infusion related reaction 42.87 10.74 44 47280 230193 79466871
Hyperuricaemia 42.06 10.74 43 47281 11756 79685308
Blood immunoglobulin M increased 41.75 10.74 19 47305 1347 79695717
Right atrial hypertrophy 41.33 10.74 16 47308 755 79696309
Blood immunoglobulin A decreased 40.63 10.74 19 47305 1434 79695630
Systemic lupus erythematosus 40.28 10.74 11 47313 121138 79575926
Cardiac failure congestive 39.20 10.74 178 47146 142224 79554840
Lower respiratory tract infection 38.92 10.74 14 47310 129206 79567858
Gastrooesophageal reflux disease 37.92 10.74 142 47182 104104 79592960
Enteritis 37.86 10.74 45 47279 14538 79682526
Gallbladder polyp 37.46 10.74 16 47308 974 79696090
Renal disorder 36.95 10.74 79 47245 42026 79655038
Synovitis 36.64 10.74 22 47302 150712 79546352
Pain 36.63 10.74 256 47068 703546 78993518
Wound 36.00 10.74 12 47312 116167 79580897
Treatment failure 34.76 10.74 30 47294 170456 79526608
Bradycardia 34.05 10.74 165 47159 135392 79561672
Prerenal failure 33.24 10.74 23 47301 3675 79693389
Pemphigus 33.19 10.74 9 47315 99573 79597491
Obstruction 33.05 10.74 25 47299 4585 79692479
Hepatic enzyme abnormal 32.55 10.74 31 47293 7779 79689285
Gastritis 32.17 10.74 81 47243 47912 79649152
Tropical sprue 32.15 10.74 5 47319 0 79697064
Interstitial lung disease 31.17 10.74 141 47183 112459 79584605
Pulmonary function test abnormal 30.88 10.74 23 47301 4121 79692943
Therapeutic product effect decreased 30.85 10.74 31 47293 163832 79533232
Diverticulum 30.76 10.74 41 47283 14855 79682209
Autoimmune enteropathy 30.12 10.74 7 47317 52 79697012
Aortic valve stenosis 30 10.74 25 47299 5269 79691795
Right ventricular hypertrophy 29.80 10.74 16 47308 1621 79695443
Rheumatic disorder 29.23 10.74 20 47304 3138 79693926
Hyperkinetic heart syndrome 28.74 10.74 8 47316 130 79696934
Exposure during pregnancy 28.72 10.74 12 47312 101120 79595944
Dizziness 28.70 10.74 455 46869 525986 79171078
Intentional product use issue 28.38 10.74 29 47295 152083 79544981
Product use in unapproved indication 28.29 10.74 67 47257 250292 79446772
Chronic kidney disease 28.24 10.74 95 47229 66059 79631005
Glossodynia 28.18 10.74 13 47311 103324 79593740
Febrile neutropenia 27.57 10.74 60 47264 230939 79466125
Hypersensitivity 27.44 10.74 73 47251 262166 79434898
Blood urea increased 27.29 10.74 77 47247 48713 79648351
Swelling 26.95 10.74 55 47269 216656 79480408
Decreased appetite 26.86 10.74 316 47008 342102 79354962
Product use issue 26.30 10.74 53 47271 209769 79487295
Erosive duodenitis 25.97 10.74 16 47308 2101 79694963
Musculoskeletal stiffness 25.74 10.74 40 47284 174968 79522096
Lymphocytic infiltration 25.01 10.74 14 47310 1539 79695525
Blood creatinine increased 24.61 10.74 167 47157 154890 79542174
Hiatus hernia 24.33 10.74 47 47277 23265 79673799
Condition aggravated 24.23 10.74 186 47138 500938 79196126
General physical health deterioration 24.22 10.74 83 47241 275155 79421909
Asthenia 24.12 10.74 432 46892 511257 79185807
Enterocolitis 24.11 10.74 36 47288 14476 79682588
Drug abuse 24.10 10.74 37 47287 162654 79534410
Large intestine polyp 23.26 10.74 33 47291 12675 79684389
Bronchial wall thickening 22.74 10.74 16 47308 2625 79694439
Atrial fibrillation 22.41 10.74 197 47127 197689 79499375
Gout 22.37 10.74 47 47277 24702 79672362
Hypoalbuminaemia 22.30 10.74 43 47281 21254 79675810
Nail disorder 22.02 10.74 31 47293 11821 79685243
Neutropenia 21.92 10.74 92 47232 287618 79409446
Abdominal discomfort 21.79 10.74 76 47248 250651 79446413
Multiple fractures 21.22 10.74 25 47299 8001 79689063
Heart rate irregular 20.71 10.74 54 47270 32625 79664439
Muscle atrophy 20.31 10.74 29 47295 11203 79685861
Gravitational oedema 20.30 10.74 13 47311 1826 79695238
Aortic dissection 20.18 10.74 18 47306 4157 79692907
Discomfort 20.15 10.74 27 47297 125590 79571474
Hypovolaemia 20.11 10.74 37 47287 17654 79679410
Pulmonary hypoplasia 19.84 10.74 5 47319 54 79697010
Metabolic acidosis 19.68 10.74 99 47225 82430 79614634
Alopecia 19.52 10.74 71 47253 231284 79465780
Disease progression 19.52 10.74 51 47273 184311 79512753
Papillary renal cell carcinoma 19.48 10.74 7 47317 268 79696796
Joint swelling 19.19 10.74 97 47227 288549 79408515
Blood glucose increased 18.94 10.74 125 47199 114850 79582214
Exercise lack of 18.68 10.74 8 47316 490 79696574
Helicobacter infection 18.65 10.74 9 47315 69695 79627369
Anaplastic astrocytoma 18.55 10.74 6 47318 166 79696898
Putamen haemorrhage 18.40 10.74 8 47316 509 79696555
Skin exfoliation 18.34 10.74 73 47251 55027 79642037
Haemorrhoids 18.32 10.74 48 47276 29080 79667984
Drug ineffective for unapproved indication 18.30 10.74 4 47320 51234 79645830
Intestinal intraepithelial lymphocytes increased 18.28 10.74 6 47318 174 79696890
Breast cancer metastatic 18.26 10.74 24 47300 8578 79688486
Gastrointestinal erosion 18.13 10.74 10 47314 1068 79695996
Cerebral haemorrhage 18.08 10.74 75 47249 57598 79639466
Contraindicated product administered 17.91 10.74 42 47282 157496 79539568
Myocardial infarction 17.69 10.74 177 47147 183952 79513112
Fibromyalgia 17.69 10.74 8 47316 64332 79632732
Infective exacerbation of chronic obstructive airways disease 17.57 10.74 14 47310 2770 79694294
Coronary artery occlusion 17.37 10.74 32 47292 15283 79681781
Liver disorder 17.36 10.74 87 47237 72330 79624734
Arthropathy 17.26 10.74 51 47273 177060 79520004
Impaired healing 17.17 10.74 16 47308 87639 79609425
Bradyphrenia 17.12 10.74 26 47298 10614 79686450
Rhabdomyolysis 16.91 10.74 112 47212 103019 79594045
Diabetic nephropathy 16.87 10.74 14 47310 2933 79694131
Infection 16.77 10.74 80 47244 241632 79455432
Bronchial secretion retention 16.56 10.74 16 47308 4088 79692976
Gluten sensitivity 16.55 10.74 7 47317 416 79696648
Diverticulitis 16.22 10.74 62 47262 45874 79651190
Multiple allergies 16.04 10.74 25 47299 10435 79686629
Generalised oedema 15.87 10.74 40 47284 23669 79673395
Hypocalcaemia 15.71 10.74 65 47259 49859 79647205
COVID-19 15.65 10.74 45 47279 157629 79539435
Drug-induced liver injury 15.54 10.74 79 47245 66038 79631026
Ill-defined disorder 15.47 10.74 10 47314 65865 79631199
Chest X-ray abnormal 15.22 10.74 21 47303 7862 79689202
Blood potassium increased 15.21 10.74 45 47279 29230 79667834
Cataract operation 15.14 10.74 17 47307 5168 79691896
Oligohydramnios 15.10 10.74 14 47310 3398 79693666
Ileal ulcer 15.04 10.74 9 47315 1121 79695943
Platelet count decreased 14.95 10.74 179 47145 194485 79502579
Bradykinesia 14.89 10.74 21 47303 8022 79689042
Hepatic enzyme increased 14.78 10.74 57 47267 182553 79514511
Leukocyturia 14.76 10.74 11 47313 1972 79695092
Lymphocytosis 14.76 10.74 16 47308 4677 79692387
Jealous delusion 14.73 10.74 6 47318 324 79696740
Hypomagnesaemia 14.70 10.74 61 47263 46850 79650214
Histology abnormal 14.68 10.74 6 47318 327 79696737
Coronary artery disease 14.54 10.74 77 47247 65397 79631667
Anti-transglutaminase antibody increased 14.47 10.74 3 47321 12 79697052
Disturbance in attention 14.47 10.74 6 47318 50795 79646269
Lymphangiectasia intestinal 14.28 10.74 3 47321 13 79697051
Blood creatine phosphokinase increased 14.18 10.74 77 47247 66013 79631051
Presyncope 14.16 10.74 55 47269 40999 79656065
Diastolic dysfunction 14.08 10.74 24 47300 10787 79686277
Gastritis erosive 14.02 10.74 24 47300 10823 79686241
Lip oedema 13.99 10.74 18 47306 6298 79690766
Autoimmune hepatitis 13.85 10.74 25 47299 11758 79685306
Cystitis 13.82 10.74 65 47259 52667 79644397
Gastric cancer 13.79 10.74 23 47301 10156 79686908
Duodenitis 13.58 10.74 20 47304 7947 79689117
Chest pain 13.50 10.74 239 47085 282065 79414999
Intestinal ulcer perforation 13.46 10.74 3 47321 18 79697046
Hospitalisation 13.41 10.74 22 47302 94214 79602850
Leukopenia 13.29 10.74 31 47293 116482 79580582
Renal cyst haemorrhage 13.26 10.74 7 47317 685 79696379
Anaemia 13.03 10.74 351 46973 444664 79252400
Iron deficiency anaemia 12.90 10.74 39 47285 25633 79671431
Loss of consciousness 12.71 10.74 154 47170 167789 79529275
Transient aphasia 12.57 10.74 6 47318 474 79696590
Aortic valve calcification 12.56 10.74 7 47317 763 79696301
Cytokine release syndrome 12.48 10.74 3 47321 35995 79661069
Encephalopathy 12.39 10.74 13 47311 67384 79629680
Confabulation 12.36 10.74 6 47318 492 79696572
Diabetes mellitus inadequate control 12.32 10.74 37 47287 24227 79672837
Erectile dysfunction 12.28 10.74 27 47297 14637 79682427
Alanine aminotransferase increased 12.27 10.74 149 47175 162421 79534643
Hypertension 12.06 10.74 269 47055 330723 79366341
Sedation 12.02 10.74 8 47316 51887 79645177
Atrophy 12.01 10.74 10 47314 2104 79694960
Adverse drug reaction 11.99 10.74 13 47311 66379 79630685
Mucosa vesicle 11.94 10.74 3 47321 32 79697032
Blister 11.93 10.74 34 47290 119442 79577622
Polyp 11.91 10.74 19 47305 8088 79688976
Glaucoma 11.85 10.74 32 47292 19729 79677335
Oedema peripheral 11.85 10.74 213 47111 252075 79444989
Orthostatic hypotension 11.76 10.74 65 47259 56099 79640965
Azotaemia 11.62 10.74 19 47305 8257 79688807
Prescribed overdose 11.58 10.74 4 47320 37879 79659185
Metastases to liver 11.50 10.74 40 47284 28274 79668790
Ischaemic enteritis 11.42 10.74 4 47320 142 79696922
Inappropriate antidiuretic hormone secretion 11.42 10.74 38 47286 26275 79670789
Product substitution issue 11.36 10.74 32 47292 20224 79676840
Thalamus haemorrhage 11.33 10.74 9 47315 1773 79695291
Eye disorder 11.24 10.74 35 47289 23377 79673687
Normochromic normocytic anaemia 11.20 10.74 18 47306 7709 79689355
Acquired oesophageal web 11.16 10.74 5 47319 342 79696722
Palmar-plantar erythrodysaesthesia syndrome 11.11 10.74 44 47280 33090 79663974
Diverticulum intestinal 11.07 10.74 19 47305 8586 79688478
Gastrointestinal hypermotility 11.06 10.74 5 47319 349 79696715
Embolic stroke 11.03 10.74 18 47306 7808 79689256
Paranasal sinus haematoma 10.94 10.74 3 47321 46 79697018
Aspartate aminotransferase increased 10.87 10.74 128 47196 138513 79558551
Cell marker increased 10.84 10.74 6 47318 645 79696419
Duodenal ulcer haemorrhage 10.82 10.74 17 47307 7146 79689918
Heart sounds abnormal 10.78 10.74 8 47316 1425 79695639

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09CA08 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
Angiotensin II receptor blockers (ARBs), plain
ATC C09DA08 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and diuretics
ATC C09DB02 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and calcium channel blockers
ATC C09DX03 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs), other combinations
FDA MoA N0000000070 Angiotensin 2 Receptor Antagonists
FDA EPC N0000175561 Angiotensin 2 Receptor Blocker
MeSH PA D047228 Angiotensin II Type 1 Receptor Blockers
MeSH PA D057911 Angiotensin Receptor Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:61016 angiotensin receptor antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Azotemia contraindication 445009001
Severe Aortic Valve Stenosis contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.25 acidic
pKa2 5.76 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Type-1 angiotensin II receptor GPCR ANTAGONIST IC50 8.10 IUPHAR CHEMBL
Type-1 angiotensin II receptor GPCR IC50 8.09 CHEMBL

External reference:

IDSource
4021345 VUID
N0000179505 NUI
D01204 KEGG_DRUG
4021344 VANDF
4021345 VANDF
C0386393 UMLSCUI
CHEBI:31932 CHEBI
CHEBI:48416 CHEBI
OLM PDB_CHEM_ID
CHEMBL1200692 ChEMBL_ID
D000068557 MESH_DESCRIPTOR_UI
C437965 MESH_SUPPLEMENTAL_RECORD_UI
7787 INN_ID
6M97XTV3HD UNII
130881 PUBCHEM_CID
DB00275 DRUGBANK_ID
118463 RXNORM
16642 MMSL
245076 MMSL
d04801 MMSL
009634 NDDF
009635 NDDF
385540001 SNOMEDCT_US
412259001 SNOMEDCT_US
412260006 SNOMEDCT_US
C1098320 UMLSCUI
CHEMBL1516 ChEMBL_ID
8612 INN_ID
144689-24-7 SECONDARY_CAS_RN
158781 PUBCHEM_CID
591 IUPHAR_LIGAND_ID
8W1IQP3U10 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5002 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5002 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5003 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5003 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5004 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5004 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5005 TABLET, FILM COATED 20 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5005 TABLET, FILM COATED 20 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5006 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5006 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2425 TABLET, FILM COATED 5 mg ORAL ANDA 31 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2425 TABLET, FILM COATED 5 mg ORAL ANDA 31 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2426 TABLET, FILM COATED 20 mg ORAL ANDA 31 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2426 TABLET, FILM COATED 20 mg ORAL ANDA 31 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2427 TABLET, FILM COATED 40 mg ORAL ANDA 31 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2427 TABLET, FILM COATED 40 mg ORAL ANDA 31 sections
Benicar HUMAN PRESCRIPTION DRUG LABEL 1 0713-0860 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Benicar HUMAN PRESCRIPTION DRUG LABEL 1 0713-0860 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Benicar HUMAN PRESCRIPTION DRUG LABEL 1 0713-0861 TABLET, FILM COATED 20 mg ORAL NDA 32 sections
Benicar HUMAN PRESCRIPTION DRUG LABEL 1 0713-0861 TABLET, FILM COATED 20 mg ORAL NDA 32 sections
Benicar HUMAN PRESCRIPTION DRUG LABEL 1 0713-0862 TABLET, FILM COATED 40 mg ORAL NDA 32 sections
Benicar HUMAN PRESCRIPTION DRUG LABEL 1 0713-0862 TABLET, FILM COATED 40 mg ORAL NDA 32 sections
Benicar HCT HUMAN PRESCRIPTION DRUG LABEL 2 0713-0863 TABLET, FILM COATED 20 mg ORAL NDA 26 sections
Benicar HCT HUMAN PRESCRIPTION DRUG LABEL 2 0713-0863 TABLET, FILM COATED 20 mg ORAL NDA 26 sections
Benicar HCT HUMAN PRESCRIPTION DRUG LABEL 2 0713-0864 TABLET, FILM COATED 40 mg ORAL NDA 26 sections
Benicar HCT HUMAN PRESCRIPTION DRUG LABEL 2 0713-0864 TABLET, FILM COATED 40 mg ORAL NDA 26 sections
Benicar HCT HUMAN PRESCRIPTION DRUG LABEL 2 0713-0865 TABLET, FILM COATED 40 mg ORAL NDA 26 sections
Benicar HCT HUMAN PRESCRIPTION DRUG LABEL 2 0713-0865 TABLET, FILM COATED 40 mg ORAL NDA 26 sections
Azor HUMAN PRESCRIPTION DRUG LABEL 2 0713-0870 TABLET, FILM COATED 20 mg ORAL NDA 26 sections
Azor HUMAN PRESCRIPTION DRUG LABEL 2 0713-0870 TABLET, FILM COATED 20 mg ORAL NDA 26 sections